Jane Street Group LLC Sells 274,078 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Jane Street Group LLC lessened its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 51.1% in the third quarter, HoldingsChannel.com reports. The firm owned 262,248 shares of the company’s stock after selling 274,078 shares during the period. Jane Street Group LLC’s holdings in Replimune Group were worth $2,874,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC grew its holdings in shares of Replimune Group by 10,304.2% during the second quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares during the last quarter. Point72 DIFC Ltd bought a new position in Replimune Group in the 2nd quarter valued at about $57,000. Arizona State Retirement System acquired a new position in Replimune Group during the 2nd quarter valued at about $108,000. Quest Partners LLC increased its holdings in Replimune Group by 30.4% during the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock worth $122,000 after purchasing an additional 3,150 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Replimune Group in the third quarter worth approximately $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of REPL stock opened at $12.49 on Friday. Replimune Group, Inc. has a 52 week low of $4.92 and a 52 week high of $17.00. The firm’s 50-day simple moving average is $12.25 and its two-hundred day simple moving average is $10.73. The firm has a market cap of $854.53 million, a price-to-earnings ratio of -4.10 and a beta of 1.26. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) EPS for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.07. As a group, equities analysts forecast that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Insider Activity

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company’s stock, valued at $2,509,013.88. The trade was a 4.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the sale, the insider now owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company’s stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their target price on Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, September 24th. BMO Capital Markets lifted their price objective on shares of Replimune Group from $14.00 to $18.00 and gave the stock an “outperform” rating in a report on Friday, November 22nd. HC Wainwright reiterated a “buy” rating and issued a $17.00 target price on shares of Replimune Group in a report on Friday, November 22nd. Jefferies Financial Group boosted their price target on shares of Replimune Group from $16.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, December 4th. Finally, Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price target of $17.29.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.